Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.

Fiche publication

Date publication

juin 2026

Journal

Therapeutic advances in neurological disorders

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Ricigliano VAG, Masmoudi I, Boudot de la Motte M, Manchon E, De Seze J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42344942

Résumé

Autoimmune (AI) comorbidities are common in people with multiple sclerosis (MS) and may complicate therapeutic management, particularly when dual immunosuppression is required. Cladribine, an immune reconstitution therapy approved for relapsing MS, has shown potential benefit in selected autoimmune disorders.